ALLIGATOR BIOSCIENCE AB - CO AND APTEVO THERAPEUTICS TODAY ANNOUNCED POSITIVE INTERIM DATA FROM DOSE ESCALATION PHASE OF THEIR PHASE 1 TRIAL EVALUATING ALG.APV-527 FOR TREATMENT OF SOLID TUMORS LIKELY TO EXPRESS TUMOR ANTIGEN 5T4

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.